scholarly journals Antiphospholipid Antibody Syndrome With Valvular Vegetations in Acute Q Fever

2015 ◽  
Vol 62 (5) ◽  
pp. 537-544 ◽  
Author(s):  
Matthieu Million ◽  
Franck Thuny ◽  
Nathalie Bardin ◽  
Emmanouil Angelakis ◽  
Sophie Edouard ◽  
...  
Keyword(s):  
Q Fever ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome ◽  
Acute Q Fever

scholarly journals Thrombosis and antiphospholipid antibody syndrome during acute Q fever

Medicine ◽  
2017 ◽  
Vol 96 (29) ◽  
pp. e7578 ◽  
Author(s):  
Matthieu Million ◽  
Nathalie Bardin ◽  
Simon Bessis ◽  
Nadia Nouiakh ◽  
Charlaine Douliery ◽  
...  
Keyword(s):  
Q Fever ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome ◽  
Acute Q Fever

scholarly journals Q-fever prosthetic valve endocarditis in a patient with SLE and antiphospholipid antibody syndrome

2020 ◽  
Vol 13 (5) ◽  
pp. 821-823 ◽  
Author(s):  
Mayyadah H. Alabdely ◽  
Noha Mukhtar ◽  
Ahmad Alshaikh ◽  
Magid Halim ◽  
Shmayel Mohammed ◽  
...  
Keyword(s):  
Prosthetic Valve ◽  
Q Fever ◽  
Prosthetic Valve Endocarditis ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome

Plasma Levels of Lipoprotein(a) Are Elevated in Patients with the Antiphospholipid Antibody Syndrome

1994 ◽  
Vol 71 (04) ◽  
pp. 424-427 ◽  
Author(s):  
Masahide Yamazaki ◽  
Hidesaku Asakura ◽  
Hiroshi Jokaji ◽  
Masanori Saito ◽  
Chika Uotani ◽  
...  
Keyword(s):  
Plasma Levels ◽  
Active Form ◽  
Plasminogen Activator Inhibitor ◽  
Arterial System ◽  
Control Group ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome ◽  
Lipoprotein A ◽  
Soluble Thrombomodulin ◽  
Relationship Of

SummaryThe mechanisms underlying clinical abnormalities associated with the antiphospholipid antibody syndrome (APAS) have not been elucidated. We measured plasma levels of lipoprotein(a) [Lp(a)], the active form of plasminogen activator inhibitor (active PAI), thrombin-antithrombin III complex (TAT) and soluble thrombomodulin (TM), to investigate the relationship of these factors to thrombotic events in APAS. Mean plasma levels of Lp(a), TAT, active PAI and TM were all significantly higher in patients with aPL than in a control group of subjects. Plasma levels of Lp(a) and active PAI were significantly higher in patients with aPL and arterial thromboses than in patients with aPL but only venous thromboses. There was a significant correlation between plasma levels of Lp(a) and active PAI in patients with aPL. These findings suggest that patients with aPL are in hypercoagulable state. High levels of Lp(a) in plasma may impair the fibrinolytic system resulting in thromboses, especially in the arterial system.

The Risk of Recurrent Venous Thromboembolism in Patients with and without Factor V Leiden

1997 ◽  
Vol 77 (04) ◽  
pp. 624-628 ◽  
Author(s):  
Sabine Eichinger ◽  
Ingrid Pabinger ◽  
Andreas Stümpfien ◽  
Mirko Hirschl ◽  
Christine Bialonczyk ◽  
...  
Keyword(s):  
Oral Anticoagulant Therapy ◽  
Oral Anticoagulants ◽  
Factor V Leiden ◽  
Multicenter Trial ◽  
Observation Time ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome ◽  
Factor V ◽  
Increased Risk ◽  
Recurrent Vte

SummaryThromboprophylaxis with oral anticoagulants up to six months is established in patients after a first venous thromboembolic event (VTE). The risk of recurrent VTE is still considerable thereafter, and it is uncertain whether some patients might benefit from extended anticoagulation. We performed a prospective, multicenter trial (4 thrombosis centers) and evaluated in 380 patients with a first or recurrent VTE (patients with a deficiency of antithrombin, protein C, protein S or plasminogen; cancer; or an antiphospholipid antibody syndrome were excluded) the risk of recurrence after discontinuation of secondary thromboprophylaxis with oral anticoagulants. It was the aim of the study to evaluate whether patients with factor V Leiden are at an increased risk of recurrent VTE. 112 (29.5%) patients were carriers of factor V Leiden (26.9% heterozygous, 2.6% homozygous). After a median observation time of 19.3 months the overall recurrence rate of VTE was 9.9%. Recurrent deep vein thrombosis and/or pulmonary embolism occurred in 26 of 268 patients without factor V Leiden (9.7%) and in 10 of 112 patients with factor V Leiden (8.9%). The probability of recurrent VTE two years after discontinuation of oral anticoagulants was 12.4% (95% Cl 7.8-17) in patients without factor V Leiden and was 10.6% (95% Cl 3.8-17.4) in carriers of the mutation. This difference was statistically not significant. Patients with factor V Leiden are not at a higher risk of recurrent VTE within two years after discontinuation of oral anticoagulants than patients without factor V Leiden. Balancing the risk of recurrent VTE and bleeding from oral. anticoagulants, patients with factor V Leiden are not likely to benefit from oral anticoagulant therapy extended beyond six months.

A Case of Systemic Sclerosis Complicated with Antiphospholipid Antibody Syndrome.

2001 ◽  
Vol 63 (3) ◽  
pp. 230-234
Author(s):  
Ryo TANAKA ◽  
Takenobu YAMAMOTO ◽  
Osamu YAMASAKI ◽  
Joji TADA ◽  
Jiro ARATA ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome

Renal arterial thrombosis and the antiphospholipid antibody syndrome: a case report

2001 ◽  
Vol 77 (6) ◽  
pp. 517-21
Author(s):  
Célia S. Macedo ◽  
Roberta S. Martinez ◽  
Márcia C. Riyuzo ◽  
Herculano D. Bastos
Keyword(s):  
Case Report ◽  
Arterial Thrombosis ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome

Q fever: a rare but potentially life-threatening zoonotic disease

2021 ◽  
Vol 14 (2) ◽  
pp. e237155
Author(s):  
Pranav Mahajan ◽  
Kailash Pant ◽  
Shirin Majdizadeh
Keyword(s):  
Chronic Disease ◽  
Cardiovascular System ◽  
Q Fever ◽  
Acute Infection ◽  
Acute Illness ◽  
Unknown Aetiology ◽  
Severe Hepatitis ◽  
The Usa ◽  
Life Threatening ◽  
Acute Q Fever

Q fever can present as a fever of unknown aetiology and can be challenging to diagnose because of the rare incidence. It can present as an acute illness with manifestations, including influenza-like symptoms, hepatitis, pneumonia or chronic disease involving the cardiovascular system. We present a case of a 39-year-old woman in the USA, who developed acute Q fever with associated sepsis and severe hepatitis. She received treatment with recovery from acute infection but currently has symptoms of post Q fever syndrome.

scholarly journals SAT0176 THERAPEUTIC APHERESIS DURING PREGNANCY IN RHEUMATIC DISEASES

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1029.2-1030
Author(s):  
A. Colpo ◽  
P. Marson ◽  
T. Tison ◽  
A. Zambon ◽  
A. La Rosa ◽  
...  
Keyword(s):  
High Risk ◽  
Adverse Events ◽  
Rheumatic Diseases ◽  
Therapeutic Option ◽  
Cardiac Activity ◽  
Successful Outcome ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome ◽  
Total N ◽  
Tertiary Center

Background:Therapeutic apheresis (TA) represents a therapeutic option in pre-existing conditions or rheumatic diseases that occur during gestation. Although pregnancy is not a contraindication itself, due to the lack of evidence-based guidelines and the alleged risk of maternal and/or fetal adverse events, there is general resistance to its application during pregnancy.Objectives:In this observational study we aimed to evaluate the efficacy and safety of TA in high-risk pregnancies in patients with rheumatic diseases, followed over a decade in a tertiary Center.Methods:Between January 2005 and April 2019, 843 TA procedures were performed during 51 pregnancies in 43 patients: 745 plasma exchange sessions and 98 immunoabsorption sessions. TA was performed in 29 (57%) pregnancies of 21 (48.8%) patients with antiphospholipid antibody syndrome (APS), in 20 (39.2%) pregnancies of 20 (46.5%) patients with congenital heart block (CHB), in 1 (1.9%) pregnancy of 1 (2.3%) patient with systemic sclerosis (SSc) and 1 (1.9%) pregnancy of 1 (2.3%) patient affected by lupic nephritis (SLE).Results:During the period considered, apheresis sessions applied to pregnant women were 7.1% of the total (n = 13.251). The average age at the first treatment was 33 years (range 24-43). The mean management age at the first apheretic treatment was 21 weeks (range 4-32). Twelve (1.4%) apheresis sessions were complicated by adverse events, none required or prolonged hospitalization. There were 44 (86.3%) live births, 3 (5.9%) spontaneous abortions and 2 (3.9%) voluntary terminations of pregnancy, 2 (3.9%) lost to follow-up. The average gestational age at birth was 35 weeks (range 24-37) and cesarean section was performed in 41 (80.4%) cases. TA was added to conventional therapy in 24/29 (82.7%) patients with APS, to the detection of fetal cardiac activity, while in 5/26 (17.3%) it was introduced when the first signs of pregnancy complications such as mild preclampsia, HELLP and IUGR were detected. TA was started within 24 hours of atrioventricular block (AVB) detection; 10/20 (50%) mothers with CHB were diagnosed with 2nd degree AVB, 9/20 (45%) with 3rd degree AVB and one (5%) with sinus bradycardia and endocardial fibroelastosis. The patient with SSc was treated with TA twice a week from the 32nd SG until delivery, which occurred at the 36th SG, due to severe IUGR and oligohydramnios. The patient with SLE complicated by lupic nephritis was treated with TA twice a week, from the 26th SG until the birth, which took place at the 31st SG.Conclusion:Our data have shown that TA in pregnancy is well tolerated. Close collaboration between rheumatologist, obstetrician and specialist in TA is essential to ensure a successful outcome of high-risk pregnancies.Disclosure of Interests: :Anna Colpo: None declared, Piero Marson: None declared, Tiziana Tison: None declared, Alessandra Zambon: None declared, Annalisa La Rosa: None declared, Ermella Zanetti: None declared, Amelia Ruffatti: None declared, Giustina De Silvestro: None declared, Ariela Hoxha Speakers bureau: Celgene, UCB, Novartis, Sanofi, Werfen

scholarly journals Ischemic colitis due to antiphospholipid antibody syndrome

2019 ◽  
Vol 19 (1) ◽  
pp. 36-38
Author(s):  
Babak Choobi Anzali ◽  
Maryam Bahreini ◽  
Behnaz Habibi ◽  
Noorieh Sharifi Sistani
Keyword(s):  
Ischemic Colitis ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome
Sign in / Sign up

Export Citation Format

Share Document